Pathogenic GLUT9 Mutations Causing Renal Hypouricemia Type 2 (RHUC2)

Abstract

Renal hypouricemia (MIM 220150) is an inherited disorder characterized by low serum uric acid levels and has severe complications such as exercise-induced acute renal failure and urolithiasis. We have previously reported that URAT1/SLC22A12 encodes a renal urate-anion exchanger and that its mutations cause renal hypouricemia type 1 (RHUC1). With the large health-examination database of the Japan Maritime Self-Defense Force, we found two missense mutations (R198C and R380W) of GLUT9/SLC2A9 in hypouricemia patients. R198C and R380W occur in highly conserved amino acid motifs in the “sugar transport proteins signatures” that are observed in GLUT family transporters. The corresponding mutations in GLUT1 (R153C and R333W) are known to cause GLUT1 deficiency syndrome because arginine residues in this motif are reportedly important as the determinants of the membrane topology of human GLUT1. Therefore, on the basis of membrane topology, the same may be true of GLUT9. GLUT9 mutants showed markedly reduced urate transport in oocyte expression studies, which would be the result of the loss of positive charges in those conserved amino acid motifs. Together with previous reports on GLUT9 localization, our findings suggest that these GLUT9 mutations cause renal hypouricemia type 2 (RHUC2) by their decreased urate reabsorption on both sides of the renal proximal tubule cells. However, a previously reported GLUT9 mutation, P412R, was unlikely to be pathogenic. These findings also enable us to propose a physiological model of the renal urate reabsorption via GLUT9 and URAT1 and can lead to a promising therapeutic target for gout and related cardiovascular diseases.

Keywords:

• Renal hypouricemia
• GLUT9/SLC2A9
• GLUT1/SLC2A1
• gout/hyperuricemia
• urate reabsorption transporter

Acknowledgments

We would like to thank all the patients who generously participated in this study. The authors thank Y. Kusanagi, S. Tadokoro, M. Nudejima, and M. Kobayashi for genetic analysis. This work was supported in part by grants from the Ministry of Defense of Japan, the Ministry of Education, Culture, Sports, Science and Technology of Japan, the Ministry of Health, Labour and Welfare of Japan, the Kawano Masanori Memorial Foundation for Promotion of Pediatrics, the Uehara Memorial Foundation, the Takeda Science Foundation, and the Gout Research Foundation of Japan.

This is a proceeding of the poster presentation at the 14th International Symposium on Purine and Pyrimidine Metabolism in Man, PP11, in Tokyo, Japan (February 18-21, 2011).